Zobrazeno 1 - 10
of 343
pro vyhledávání: '"Jungsil Ro"'
Autor:
Johannes Ettl, Seock-Ah Im, Jungsil Ro, Norikazu Masuda, Marco Colleoni, Patrick Schnell, Eustratios Bananis, Dongrui R. Lu, Massimo Cristofanilli, Hope S. Rugo, Richard S. Finn
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-10 (2020)
Abstract Background Palbociclib improves outcomes for women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC). Dose reductions are recommended for the management of hematolog
Externí odkaz:
https://doaj.org/article/c9f4326e37ad41e7874ee10f377c5ba6
Autor:
Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, Young-Hyuck Im, Kenichi Inoue, Yoshiaki Rai, Rikiya Nakamura, Jee Hyun Kim, Justin T. Hoffman, Ke Zhang, Carla Giorgetti, Shrividya Iyer, Patrick T. Schnell, Cynthia Huang Bartlett, Jungsil Ro
Publikováno v:
Journal of Global Oncology, Vol 3, Iss 4, Pp 289-303 (2017)
Purpose: To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy–resistant metastatic breast cancer. Patients and Methods: The Palbociclib Ongoing Trials in the Management of Breast Cancer 3 (PALOMA-3) trial,
Externí odkaz:
https://doaj.org/article/1f649be8218b4119bec32926794f26b2
Autor:
Mark D. Pegram, Sanne L. de Haas, Steve Olsen, Meghna K. Samant, Alice E. Guardino, Jens Huober, Jungsil Ro, Sunil Verma, Gail D. Lewis Phillips, José Baselga
Purpose: HER2-positive breast cancer is heterogeneous. Some tumors express mutations, like activating PIK3CA mutations or reduced PTEN expression, that negatively correlate with response to HER2-targeted therapies. In this exploratory analysis, we in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60a7b946dd1897f953de04735e267dbc
https://doi.org/10.1158/1078-0432.c.6523352.v1
https://doi.org/10.1158/1078-0432.c.6523352.v1
Autor:
Mark D. Pegram, Sanne L. de Haas, Steve Olsen, Meghna K. Samant, Alice E. Guardino, Jens Huober, Jungsil Ro, Sunil Verma, Gail D. Lewis Phillips, José Baselga
Supplementary Fig 1. Overall survival by HER2 mRNA percentile Supplementary Fig 2. Patient disposition and biomarker availability in the EMILIA trial. Supplementary Fig 3. Potential mechanism by which T-DM1 may bypass a common resistance pathway in H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90a392182694566c21ada6ef2478bd88
https://doi.org/10.1158/1078-0432.22456571.v1
https://doi.org/10.1158/1078-0432.22456571.v1
Autor:
Sung Hoon Sim, Chang-Dae Bae, Youngmi Kwon, Hai-Li Hwang, Shiv Poojan, Hye-In Hong, Kyungtae Kim, Seo-Hee Kang, Han-Seong Kim, Tae-Hyun Um, In Hae Park, Keun Seok Lee, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Mi-Kyung Kim, Kyeong-Man Hong, Jungsil Ro
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0182107 (2017)
Recently, we reported cytoskeleton-associated protein2 (CKAP2) as a possible new prognostic breast cancer marker. However, it has not yet been applied in clinic. Therefore, clinical significance of CKAP2 was evaluated in comparison with that of Ki-67
Externí odkaz:
https://doaj.org/article/4e6c5718b3ea4af38b8abbd539e35163
Autor:
Seohyun Lee, Arlene Lansangan Quiambao, Jeonghee Lee, Jungsil Ro, Eun-Sook Lee, So-Youn Jung, Mi-Kyung Sung, Jeongseon Kim
Publikováno v:
Nutrients, Vol 11, Iss 8, p 1949 (2019)
Breast cancer is the most common cancer in women globally, and the risk of developing breast cancer is associated with inflammation. The present study aimed to examine the association between the Dietary Inflammatory Index (DII®) and breast cancer i
Externí odkaz:
https://doaj.org/article/dba15dc280d9421a873cd35e80012cf0
Autor:
Yeon Hee Park, In Hae Park, Keun Seok Lee, Sung Hoon Sim, Kyung Hae Jung, Kyong Hwa Park, Young-Hyuck Im, Sung Bae Kim, Hee Jun Kim, Joohyuk Sohn, Jungsil Ro, Jin-Hee Ahn, Yee Soo Chae, Seock Ah Im, Yu Jung Kim, Kyung Hun Lee, Suee Lee, Byung-Ho Nam
Publikováno v:
British Journal of Cancer
Background The continuum of anti-HER2 agents is a standard treatment of HER2 + metastatic breast cancer (MBC). This study evaluated the efficacy of lapatinib plus vinorelbine in patients progressed on both trastuzumab and lapatinib treatments. Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::055f092c6f931bb82aeb534f08f3e2b8
https://doi.org/10.1038/s41416-019-0618-z
https://doi.org/10.1038/s41416-019-0618-z
Autor:
Ting Ying Ng, Sarah Park, Tae You Kim, Moon Hee Lee, Joanne Chiu, Gyungyub Gong, Christos Nathaniel, Janice Tsang, Kyong Hwa Park, In Gu Do, Young Jin Choi, Yoon Sim Yap, Jungsil Ro, Joohyuk Sohn, Sung Bae Kim, Gerardo H. Cornelio, Soonmyung Paik, Suee Lee, Ho Suk Oh, Eun Mi Lee
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose BioPATH is a non-interventional study evaluating the relationship of molecular biomarkers (PTEN deletion/downregulation, PIK3CA mutation, truncated HER2 receptor [p95HER2], and tumor HER2 mRNA levels) to treatment responses in Asian patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfb41273514b2d44569de9831fb2f412
https://doi.org/10.4143/crt.2018.598
https://doi.org/10.4143/crt.2018.598
Autor:
Jungsil Ro, J-H Ahn, KS Lee, S-B Kim, K-H Lee, In Hae Park, KH Park, Y.S. Chae, Young-Ae Park, Sung Hoon Sim, S Lee, Jung Ho Sohn, KH Jung, Y-H Im, Hj. Kim, B-H Nam, S-A Im, Y. Kim
Publikováno v:
Cancer Research. 79:P6-17
Background The continuum of anti-HER2 agents is regarded as a standard strategy for HER2 positive metastatic breast cancer patients who had progressed disease with anti-HER2 agent- containing treatments. However, there has been lack of data on which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf4aabac4316b9f75d1bd7ab4af85c5c
https://doi.org/10.1158/1538-7445.sabcs18-p6-17-23
https://doi.org/10.1158/1538-7445.sabcs18-p6-17-23
Autor:
Junichiro Watanabe, Youngsen Yang, Hiroji Iwata, Koichiro Tsugawa, Sung-Bae Kim, Yoshihiro Nambu, Yutaka Tokuda, Shoichiro Ohtani, Toshiaki Saeki, Jungsil Ro, Yeon Hee Park, Yasuhiro Fujiwara, Yung-Chang Lin, Katsumasa Kuroi, Keun Seok Lee, Shigenori Nagai, Hirofumi Mukai
Publikováno v:
British Journal of Cancer
Background NK105 is a novel nanoparticle drug delivery formulation that encapsulates paclitaxel (PTX) in polymeric micelles. We conducted an open-label phase III non-inferiority trial to compare the efficacy and safety of NK105 and PTX in metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f70b1fa8c4669f919de5ba131da8c7c2
https://doi.org/10.1038/s41416-019-0391-z
https://doi.org/10.1038/s41416-019-0391-z